Epidemiological Status of Thyroid Eye Disease in Central Iran

被引:3
|
作者
Eshraghi, Bahram [1 ]
Nikdel, Mojgan
Abbasi, Maryam [1 ]
机构
[1] Isfahan Univ Med Sci, Isfahan Eye Res Ctr, Dept Ophthalmol, Esfahan, Iran
来源
JOURNAL OF CURRENT OPHTHALMOLOGY | 2022年 / 34卷 / 01期
关键词
Graves' disease; Proptosis; Thyroid eye disease; Thyroid orbitopathy; Thyroid-associated ophthalmopathy; GRAVES OPHTHALMOPATHY; EUROPEAN GROUP; ORBITOPATHY; MANAGEMENT; SEVERITY; PATHOGENESIS; PREVALENCE; CRITERIA; UPDATE; AGE;
D O I
10.4103/joco.joco_223_21
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
Purpose: To focus on clinical manifestations and epidemiology of thyroid eye disease (TED) in Central Iran's population. Methods: In this retrospective case study, we analyzed all patients with TED who were referred to our oculoplastic clinic from 2015 to 2019. The patients' epidemiological characteristics and clinical presentation were compared between different thyroid disease groups and genders. Results: Overall, 383 patients (155 male; 40.5% and 228 female; 59.5%) were included. The mean age was 39.55 years (standard deviation +/- 13.45, range 10-72). Most patients (89%) were hyperthyroid with the highest duration of ocular involvement among all categories (25.6 months). The most common signs on ophthalmic examinations were proptosis (80.4%), followed by eyelid retraction (72.3.0%). TED was classified as mild in 24.5%, moderate to severe in 67.6%, and sight-threatening in 7.9%. Thirty patients (7.8%) had active TED. Conclusions: This series with a relatively more significant number of TED cases in Central Iran found similar epidemiological and clinical characteristics of TED compared to other studies from Iran. Most of our patients were hyperthyroid, with more females compared to males. Proptosis and eyelid retraction were the most common manifestations. Most TED patients were classified as moderate to severe.
引用
收藏
页码:106 / 111
页数:6
相关论文
共 50 条
  • [31] Adipogenesis in thyroid eye disease
    Crisp, M
    Starkey, KJ
    Lane, C
    Ham, J
    Ludgate, M
    [J]. INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2000, 41 (11) : 3249 - 3255
  • [32] Tocilizumab for thyroid eye disease
    Azzam, Shirin Hamed
    Kang, Swan
    Salvi, Mario
    Ezra, Daniel G.
    [J]. COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2018, (11):
  • [33] Rituximab for Thyroid Eye Disease
    Silkiss, Rona Z.
    Reier, Alice
    Coleman, Morton
    Lauer, Simeon A.
    [J]. OPHTHALMIC PLASTIC AND RECONSTRUCTIVE SURGERY, 2010, 26 (05): : 310 - 314
  • [34] EYE CHANGES WITH THYROID DISEASE
    HENDERSON, JW
    [J]. POSTGRADUATE MEDICINE, 1969, 45 (05) : 96 - +
  • [35] An overview of thyroid eye disease
    McAlinden, Colm
    [J]. EYE AND VISION, 2014, 1
  • [36] Thyroid eye disease: a review
    Weiler, Danielle L.
    [J]. CLINICAL AND EXPERIMENTAL OPTOMETRY, 2017, 100 (01) : 20 - 25
  • [37] Treatment of Thyroid Eye Disease
    Margaret E. Phillips
    Mehrak M. Marzban
    Sajeev S. Kathuria
    [J]. Current Treatment Options in Neurology, 2010, 12 : 64 - 69
  • [38] DIPLOPIA IN THYROID EYE DISEASE
    FELLS, P
    MCCARRY, B
    [J]. TRANSACTIONS OF THE OPHTHALMOLOGICAL SOCIETIES OF THE UNITED KINGDOM, 1986, 105 : 413 - 423
  • [39] Management of thyroid eye disease
    Luigi Bartalena
    Claudio Marcocci
    Maria Tanda
    Aldo Pinchera
    [J]. European Journal of Nuclear Medicine and Molecular Imaging, 2002, 29 : S458 - S465
  • [40] Immunotherapies for thyroid eye disease
    Kahaly, George J.
    [J]. CURRENT OPINION IN ENDOCRINOLOGY DIABETES AND OBESITY, 2019, 26 (05) : 250 - 255